News

Menopause HRT patches show promise for prostate cancer treatment by suppressing testosterone, though they cause feminizing side effects.

Clarivate analyzes orforglipron and retatrutide, next-gen GLP-1 drugs offering oral delivery and triple-hormone action for diabetes and obesity.

Johns Hopkins study finds GLP-1 drugs improve heart and kidney outcomes in type 1 diabetes patients beyond blood sugar control.

Midlife women are seeking testosterone therapy for severe cognitive symptoms during menopause, including debilitating brain fog.

Wellness seekers inject unregulated peptides marked “research only,” bypassing safety testing despite serious health risks, BBC finds.

New data suggests semaglutide may reduce suicide risk in diabetes patients, contrary to earlier safety concerns about GLP-1 medications.

Oral semaglutide reduces cardiovascular risk factors in type 2 diabetes patients, offering effective protection in tablet form.

Peptide wellness claims are surging on social media, with users reporting dramatic energy boosts despite limited evidence and regulatory oversight.

Systematic review explores safety of scorpion venom peptides for cardiovascular treatment, highlighting both promise and challenges.

Kendra Wilkinson announced she’s beginning GLP-1 treatment, adding to growing celebrity transparency about weight management medications.